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Melatonin increased vitamin C and antioxidant enzyme values in the plasma,
heart, liver, and kidney of Adriamycin-treated rats
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Abstract: Adriamycin, an anticarcinogenic agent, causes excessive production of reactive oxygen species (ROS). These radicals may
affect antioxidant defense systems. The present study was designed to investigate the effects of melatonin on antioxidant enzyme
activities and vitamin C in Adriamycin-treated rats. In the current study, rats were divided into three groups: control, Adriamycin,
and melatonin+Adriamycin groups. The control group was intraperitoneally injected physiological saline (0.9%) as a placebo. The
Adriamycin and melatonin+Adriamycin groups were administered Adriamycin (25 mg/kg body weight). The melatonin+Adriamycin
group was pretreated with melatonin (0.5 mg/kg body weight). Vitamin C concentration and catalase (CAT), superoxide dismutase
(SOD), glutathione peroxidase (GSH-Px), glutathione reductase (GR), and myeloperoxidase (MPO) activities were determined in the
plasma, heart, liver, and kidneys in the Adriamycin-treated rats. The activities of CAT, SOD, GSH-Px, GR, and MPO decreased generally
(between P < 0.045 and P < 0.006) with Adriamycin treatment, but these enzymes were near to the control values with melatonin
treatment. In conclusion, melatonin inhibited Adriamycin-induced ROS production through supporting antioxidant enzyme systems
in the plasma, heart, liver, and kidneys of rats, and thus may play an important role against Adriamycin toxicity.
Key words: Adriamycin, melatonin, antioxidant enzymes, heart, liver, kidney, rat

1. Introduction
Adriamycin is an important chemotherapeutic agent used
for treatment of some cancer varieties, but it has seriously
toxic effects in especially in the heart (Koçkar et al., 2010;
Uguz et al., 2012; Zang et al., 2013; Bilginoglu et al.,
2014), liver (Aydoğan et al., 2013; Lee et al., 2013), kidney
(Hrenak et al., 2013; Escribano et al., 2014), and other
tissues (Agopito et al., 2001). However, the mechanism
of Adriamycin toxicity is not completely understood.
Several mechanisms have been suggested to explain
Adriamycin cytotoxicity (Gewirtz et al., 1999), including
stabilization of DNA-topomerase complex (Guano et al.,
1999), intercalation into DNA (Kiyomiya et al., 2001), and
increasing of reactive oxygen species and semiquinone
radicals induced by Adriamycin (Kalyanaraman et al.,
2002; Othman et al., 2008). Adriamycin is transformed
to semiquinone free radicals by the NADPH-cytochrome
P450 microsomal system. NADPH-dependent reductase
converts Adriamycin to semiquinone free reactive radicals
(Vora et al., 1996). Increasing of these radicals during
biotransformation of Adriamycin may play a major role in
Adriamycin-induced toxicity (Monti et al., 1996; Vora et
* Correspondence: azkar@harran.edu.tr

al., 1996), causing oxidative stress of cellular components
in cardiac (Kim et al., 2005; Özdoğan et al., 2011; Zang et
al., 2013), hepatic (Aydoğan et al., 2013; Lee et al., 2013),
and renal tissues (Hrenak et al., 2013; Escribano et al.,
2014).
Oxidative stress is characterized as an imbalance
between antioxidant defense systems and reactive oxygen
species and nitrogen reactive substances (Nazıroğlu, 2007,
2015). One practice used for minimizing the oxidative
stress induced by Adriamycin is the administration of
some antioxidants to experimental animals. Melatonin, an
important natural antioxidant, may reduce oxidative stress
induced by Adriamycin (Othman et al., 2008) and other
stimulative agents (Naziroğlu et al., 2012, Senol et al., 2014).
It has been reported that Adriamycin affected the activities
of CAT, SOD, GSH-Px, and GR in experimental animals
(Özdoğan et al., 2011; Lee et al., 2013; Zang et al., 2013).
There are many reports documenting protective effects of
melatonin on experimental Adriamycin toxicity (Othman
et al., 2008; Lee et al., 2013). Melatonin may diminish the
cytotoxic effects of the intermediary reactive metabolites
produced during biotransformation of Adriamycin in the
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cytochrome P450 microsomal system. Thus, melatonin
can scavenge efficiently free radicals before they initiate
oxidative damage in cellular components and contributes
to physiological functions of the antioxidant defensive
system. Therefore, the present study was carried out to
investigate the probable effects of melatonin on vitamin
C concentrations and CAT, SOD, GSH-Px, GR, and MPO
activities in the cardiac, hepatic, and renal tissues and
plasma of rats experimentally treated with Adriamycin.
2. Materials and methods
2.1. Animals and treatments
This study was conducted with rats (Wistar albino) aged
2–2.5 months that weighed 150–200 g. All the rats were
fed rodent pellets and water ad libitum, and were housed
in cages at room temperature with a light/day cycle.
Animal housing and the experiments were conducted
in accordance with the Guide for the Care and Use of
Laboratory Animals. All rats (n = 24) were randomly
divided into three groups. The first group (n = 8) was
the control group and physiological saline (0.9%) was
intraperitoneal injected into these animals as a placebo.
The second group (n = 8) was the Adriamycin group and
only Adriamycin was injected (25 mg/kg body weight).
The third group (n = 8) received intraperitoneally injected
Adriamycin (25 mg/kg body weight) and melatonin (0.5
mg/kg body weight). All chemicals were of analytical
grade and were purchased from Sigma Chemical Co. (St.
Louis, MO, USA) and Merck Chemical Co. (Darmstadt,
Germany). The Adriamycin and melatonin treatments
were applied every other day during the study. After 24
h of the last dose being administered on day 10, blood
samples were taken under ether sedation.
2.2. Preparation of plasma and tissue samples
Twenty-four hours after the last dose was administered,
blood samples were taken by cardiac puncture under
ether sedation; then the animals were sacrificed under
ether anesthesia. Blood samples were obtained via cardiac
puncture 24 h after the last application of Adriamycin and
melatonin. Whole blood was collected into heparinized
tubes (Becton Dickinson Vacutainer System, France)
and subsequently centrifuged at 1500 × g for 15 min in a
Heraeus Megafuge 10. Their plasma samples were placed
in disposable pipettes and stored at –80 °C for further
biochemical analysis. The abdomens of all rats were opened
via laparotomy and their livers, hearts, and kidneys were
removed. These organs were then rinsed quickly in cold
saline solution and divided into two halves. These tissues
were homogenized and they were frozen at –80 °C until
the antioxidant enzymes assays. Then the enzyme activities
and vitamin C concentrations in the plasma, heart, liver,
and kidneys samples were determined.
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2.3. Biochemical analyses
The abdomens of all rats were opened and their hearts,
liver, and kidneys were removed. These tissues were stored
at –80 °C for further biochemical analysis. All the analyses
were conducted as suggested by the manufacturers of
commercial kits. Catalase (CAT) activity was assayed
according to Goth (1991). Myeloperoxidase activity in the
tissue specimens was analyzed according to Krawisz et al.
(1984). Total SOD activity was determined as reported by
Sun et al. (1988). GSH-Px activity was measured using the
method described by Paglia and Valentine (1967), while
GR activity was measured using the method described by
Carlberg et al. (1986). Protein contents were measured
according to the method of Lowry et al. (1951). Vitamin
C concentrations were measured according to the method
reported by Omaye et al. (1979). All antioxidant enzymes
were analyzed by spectrophotometry (Jenway 6800 UV1175, China).
2.4. Statistical analysis
Statistical analysis was performed using SPSS v.11.5 (SPSS,
Inc., Chicago, IL, USA). The data were expressed as means
± standard deviation (SD). Differences between group
means were estimated using one way analysis of variance
followed by Mann–Whitney U-test and the results were
considered to be statistically significant at P < 0.05.
3. Results
The activities of CAT, SOD, GSH-Px, GR, and MPO
enzymes in the plasma, heart, liver, and kidneys are
presented in Tables 1–4. Vitamin C concentrations in the
plasma, heart, liver, and kidneys are shown in Figures
1A–1D.
The activities of CAT, SOD, GSH-Px, GSH-Rx, and
MPO and vitamin C in plasma decreased significantly
with Adriamycin treatment, while CAT, SOD, and
MPO activities and vitamin C concentration increased
significantly (Table 1; Figure 1A). GSH-Px and GSH-Rx
activities were not affected (almost the level observed in the
control group) by Adriamycin plus melatonin treatment.
In cardiac tissue, while CAT and SOD activities
decreased significantly, GSH-Px, GR, and MPO activities
increased in response to Adriamycin. In addition, SOD
increased, MPO decreased significantly, and CAT, GSHPx, GR and vitamin C were not affected by Adriamycin
plus melatonin treatment (Table 2).
In hepatic tissue, while CAT, GSH-Px, and MPO
activities increased significantly in response to Adriamycin,
SOD and GR were decreased significantly by Adriamycin.
In addition, while the activities of CAT, GSH-Px, GR, and
MPO decreased, the values of SOD significantly increased
in response to Adriamycin plus melatonin treatment
(Table 3).
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Table 1. Effects of melatonin on catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px),
glutathione reductase (GR), and myeloperoxidase (MPO) activities in plasma of Adriamycin-treated rats (n = 8).
Parameters/Groups

Control

Adriamycin

Adriamycin+melatonin

CAT, U/L

649.04± 103.63

487.28±113.26

SOD, U/L

73.44± 9.32

56.26± 7.41b

73.47± 6.02g

GSH-Px, U/L

398.98± 69.06

227.46± 125.25c

235.47± 123.43a

GR, U/L

42.14± 6.16

29.84± 6.46c

26.30± 3.71e

MPO, U/L

73.84± 19.47

37.84± 9.82d

68.83± 25.61h

693.27± 16.40f

a

Data are presented as mean ± SD.
Statistical significance versus control group, aP < 0.046, bP < 0.036, cP < 0.028, dP < 0.016.
Statistical significance versus Adriamycin group, eP < 0.049, fP < 0.006, gp < 0.011, hP < 0.052.

Table 2. Effects of melatonin on catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px),
glutathione reductase (GR), and myeloperoxidase (MPO) activities in cardiac tissue of Adriamycin-treated rats (n = 8).
Parameters/Groups

Control

Adriamycin

Adriamycin+melatonin

CAT, U/g protein

548.32± 41.86

398.80± 49.96

319.27± 147.37c

SOD, U/g protein

6.37± 0.68

5.73± 0.53a

7.16± 0.25b,e

GSH-Px, U/g protein

122.97± 7.93

157.42± 16.18b

147.42± 18.95a

GR, U/g protein

39.97± 12.32

50.26± 6.83b

50.84± 7.62c

MPO, U/g protein

8.02± 1.20

15.65± 0.67b

9.23± 2.36e

b

Data are presented as mean ± SD.
Statistical significance versus control group, aP < 0.046, bP < 0.009, cP < 0.006.
Statistical significance versus Adriamycin group, dP < 0.047, eP < 0.006.

Table 3. Effects of melatonin on catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px),
glutathione reductase (GR), and myeloperoxidase (MPO) activities in hepatic tissue of Adriamycin-treated rats (n = 8).
Parameters/Groups

Control

Adriamycin

Adriamycin+melatonin

CAT, U/g protein

4.24± 2.90

9.92± 4.13b

67.72± 33.93b,g

SOD U/g protein

5.12± 0.29

4.67± 0.56a

5.57± 0.25a,f

GSH-Px, U/g protein

31.18± 18.81

68.59± 19.33a

59.99± 21.51e

GR, U/g protein

212.88± 9.87

198.12± 16.04a

178.63± 16.63d,e

MPO, U/g protein

6.44± 0.84

11.51± 3.03c

7.25± 2.55d,f

Data are presented as mean ± SD.
Statistical significance versus control group, aP < 0.046, bP < 0.027, cP < 0.009, dP < 0.006.
Statistical significance versus Adriamycin group, eP < 0.045, fP < 0.017, gP < 0.009.
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Table 4. Effects of melatonin on catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px),
glutathione reductase (GR), and myeloperoxidase (MPO) activities in renal tissue of Adriamycin-treated rats (n = 8).
Parameters/Groups

Control

Adriamycin

Adriamycin+melatonin

CAT, U/g protein

95.80± 13.92

10.76± 4.03

109.90± 17.83e

SOD, U/g protein

5.94± 0.41

6.30± 0.81

6.79± 0.61

GSH-Px, U/g protein

154.45± 31.84

85.80± 8.75

139.90± 13.69e

GR, U/g protein

215.98± 67.85

222.87± 21.65

212.74± 80.41

MPO, U/g protein

5.42± 1.45

13.22± 3.71c

6.67± 1.38e

b

Data are presented as mean ± SD.
Statistical significance versus control group, aP < 0.045, bP < 0.016, cP < 0.009.
Statistical significance versus Adriamycin group, dP < 0.044, eP < 0.006.

Figure 1. Vitamin C concentrations in (A) plasma, (B) heart, (C) liver, and (D) kidney in all groups.
Data are presented as mean ± SD.
CONT: Control; ADR: Adriamycin; MEL: Melatonin.
Statistical significance versus control group, aP < 0.018, bP < 0.010.
Statistical significance versus Adriamycin group, cP < 0.044.

In renal tissue, while GSH-Px activity decreased
significantly, MPO activity increased, but CAT, SOD,
and GSH-Rx activities were not affected by Adriamycin.
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Moreover, while GSH-Px was increased significantly, MPO
was decreased significantly by Adriamycin plus melatonin
treatment (Table 4).
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4. Discussion
Several authors have confirmed the protective effect
of melatonin on different tissues during Adriamycin
intoxication (Agopito et al., 2001; Zang et al., 2013;
Bilginoglu et al., 2014). Adriamycin is highly toxic to
the heart, liver, kidney, and small intestine. Studies
have suggested that melatonin scavenged the highly
toxic hydroxyl radicals induced by Adriamycin (Tan
et al., 1998; Agopito et al., 2001; Othman et al., 2008)
and other stimulants (Naziroğlu et al., 2012, Senol et
al., 2014). Furthermore, Adriamycin is transformed to
semiquinone free radicals by the NADPH-cytochrome
P450 microsomal system. NADPH-dependent reductase
converts Adriamycin to semiquinone free radicals,
which then leads to the generation of superoxide anion
and hydroxyl radicals damaged to cellular lipids and
lipoproteins. These radicals may play an important role
in Adriamycin-induced cytotoxicity (Vora et al., 1996;
Agopito et al., 2001; Lee et al., 2013). Thus, Adriamycininduced toxicity may contribute to a reduction in the
antioxidant defense system in the heart and other tissues
due to oxidative damage from these free radicals (Özdoğan
et al., 2011).
It has been reported that the values of SOD and GSH-Px
may be important indicators in myocardial injury related
to the degree of Adriamycin toxicity (Floyd et al., 2005).
In the present study, plasma activities of CAT, SOD, GSHPx, and GR were decreased significantly in response to
Adriamycin (Table 1). In addition, MPO activity decreased
in plasma, but cardiac, hepatic, and renal MPO activities
were increased significantly in response to Adriamycin. In
addition, hepatic CAT and GSH-Px activities increased,
and SOD and GR activities decreased significantly in
response to Adriamycin (Tables 2–4). These results are
consistent with those of studies reporting increased
activities of MPO (El Berry et al., 2010) and CAT, SOD,
and GSH-Px with Adriamycin induction (Özdoğan et al.,
2011; Lee et al., 2013).
Melatonin, an important hormone of the pineal
gland, is produced by various other tissues including
the retina (Tosini and Menaker, 1998), gastrointestinal
tract (Bubenik, 2002), skin (Slominski et al., 2005),
lymphocytes (Carrillo-Vico et al., 2004), and bone marrow
(Conti et al., 2000). The antioxidant activity of melatonin
has been described to occur by two different mechanisms:
(1) melatonin directly scavenges •OH radicals (Kim et
al., 2005) and (2) melatonin reduces oxidative stress by
stimulating antioxidant enzymes (Reiter et al., 1997).
Oxidative stress is characterized as an imbalance between
antioxidant defense systems and reactive oxygen species
(ROS) generated during many aerobic physiological
processes such as mitochondrial electron transfer
reactions, phagocytic activity, and nitrogen reactive
substances (Nazıroğlu, 2007, 2009).

CAT is an antioxidant defense enzyme and a
potent H2O2 scavenger. This enzyme may prevent the
formation of highly toxic hydroxyl radicals (Yabe et
al., 2001; Aydoğan et al., 2013). Thus, the production of
CAT provides additional antioxidative activity against
oxidative stress during oxidative injury. In the present
study, hepatic activities of CAT, GSH-Px, GR, and MPO
decreased significantly with melatonin treatment (Table
3). In contrast, CAT activity in the plasma and kidney
significantly increased with melatonin treatment (Tables
1 and 4). In the present study, SOD activity increased
significantly in the plasma, heart, and liver; renal GSHPx increased; and renal MPO decreased with melatonin
treatment (Table 4). These findings are partially consistent
with the results concerning decreases in CAT, SOD, and
GSH-Px with melatonin (Özdoğan et al., 2011; Lee et al.,
2013). The accumulating evidence implicates a modulatory
role of melatonin on excessive oxidative stress induced
in Adriamycin toxicity (Othman et al., 2008; Lee et al.,
2013; Escribano et al., 2014) and some stimulative agents
(Nazıroğlu et al., 2012; Şenol et al., 2014; Nazıroğlu, 2015).
Plasma antioxidants may be more susceptible than
tissue antioxidants to Adriamycin toxicity and melatonin
treatment. Adriamycin-induced oxidative damage may
increase ROS such as superoxide (O2.–), hydroxyl radical
(OH–), hydrogen peroxide (H2O2), and other free oxygen
radicals. The mechanism underlying this cytotoxicity
seems to be linked to an increased production of ROS and
oxidative damage (Berthiaume and Walke, 2007; Özdoğan
et al., 2011). In plasma samples, while vitamin C decreased
in response to Adriamycin, this antioxidant vitamin was
increased significantly by melatonin treatment (Figure
1A). Furthermore, cardiac, hepatic, and renal vitamin C
values were not affected by melatonin treatment (Figures
1B–1D). It has been reported that vitamin C decreased
oxidative stress (lipid hydroperoxides and total oxidant
status and oxidative stress index) induced by acetic acid
in rats (Zerin et al., 2010). Vitamin C is a well-known
antioxidant that has been shown to efficiently scavenge free
oxygen radicals, including superoxide, hydrogen peroxide,
hypochlorite, hydroxyl, peroxyl, and singlet oxygen. Thus,
vitamin C may diminish certain types of lipid peroxidation
and may play a major role in preventing oxidative stress
in cardiac, hepatic, and renal tissues of rats (Loo et al.,
2003). All these results may provide scientific support
in understanding the protective effects of melatonin on
plasma antioxidants in oxidative damage produced due to
Adriamycin toxicity.
In conclusion, the present study indicated that
Adriamycin and melatonin affected antioxidant enzymes
and plasma vitamin C concentration. Increasing free
oxygen radicals due to peroxidation reactions produced
during Adriamycin biotransformation may increase
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oxidative damage in the cellular components of living
organisms. Thus, melatonin may play an important
protective role against Adriamycin toxicity in the plasma,
heart, liver, and kidney. This protective role may be due
to both decreasing of oxidative stress and induction
of some antioxidant enzymes. Chemotherapy with
Adriamycin may cause a risk of cardiac, hepatic, and
renal damage. Therefore, melatonin may be a therapeutic
adjuvant that may modulate oxidative stress induced by
Adriamycin toxicity. However, there is a need for more
detailed studies in order to assess possible relationships
between antioxidants and Adriamycin-induced toxicity.
We have been considering the possibility that antioxidant

administration (like β-carotene and vitamin E) may have
a prophylactic role in modulation of complications in
Adriamycin toxicity. Therefore, we are presently continuing
our studies investigating the effects of Adriamycin toxicity.
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